DOI QR코드

DOI QR Code

Overview of Gingival Overgrowth in Transplant Patients

  • Park, Seo-Jin (Department of Periodontics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Park, Jun-Beom (Department of Periodontics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Ko, Young-Kyung (Department of Periodontics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • 발행 : 2012.06.30

초록

Patients with gingival overgrowth are easily seen in dental clinics. Cyclosporin-A (CsA), a widely prescribed immunosuppressant induces gingival overgrowth in up to 35% of patients with medical history of organ transplantation. The immunosuppressant CsA can transform genetic expression of gingival fibroblasts, resulting in gingival overgrowth. Meticulous plaque control is recommended for treatment of gingival overgrowth. Substitution of the drug or surgical procedures such as gingivectomy and periodontal flaps should be considered after re-evaluation. Azithromycin is often recommended as a supplementary drug to reduce this side effect. Recent studies show that tacrolimus can be a more economic, efficient and safe substitute for CsA.

키워드

참고문헌

  1. Korean Network for Organ Sharing: 2010 annual report on organ sharing. Seoul: Korea Network for Ogran Sharing (KONOS); 2010.
  2. Britton S, Palacios R. Cyclosporin A--usefulness, risks and mechanism of action. Immunol Rev. 1982; 65: 5-22. https://doi.org/10.1111/j.1600-065X.1982.tb00425.x
  3. Seymour RA, Thomason JM, Nolan A. Oral lesions in organ transplant patients. J Oral Pathol Med. 1997; 26: 297-304. https://doi.org/10.1111/j.1600-0714.1997.tb00219.x
  4. King GN, Fullinfaw R, Higgins TJ, Walker RG, Francis DM, Wiesenfeld D. Gingival hyperplasia in renal allograft recipients recei ving cyclosporin-A and calcium antagonists. J Clin Periodontol. 1993; 20:286-93. https://doi.org/10.1111/j.1600-051X.1993.tb00360.x
  5. Thomason JM, Seymour RA, Rice N. The prevalence and severity of cyclosporin and nifedipine-induced gingival overgrowth. J Clin Periodontol. 1993; 20: 37-40. https://doi.org/10.1111/j.1600-051X.1993.tb01757.x
  6. Thomason JM, Kelly PJ, Seymour RA. The distribution of gingival overgrowth in organ transplant patients. J Clin Periodontol. 1996; 23: 367-71. https://doi.org/10.1111/j.1600-051X.1996.tb00559.x
  7. Nakib N, Ashrafi SS. Drug-induced gingival overgrowth. Dis Mon. 2011; 57: 225-30. https://doi.org/10.1016/j.disamonth.2011.03.010
  8. Feehally J, Walls J, Mistry N, Horsburgh T, Taylor J, Veitch PS, Bell PR. Does nifedipine ameliorate cyclosporin A nephrotoxicity? Br Med J (Clin Res Ed). 1987; 295: 310. https://doi.org/10.1136/bmj.295.6593.310
  9. Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowths. Aust Dent J. 1999; 44: 219-32. https://doi.org/10.1111/j.1834-7819.1999.tb00224.x
  10. Hassell TM, Hefti AF. Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Biol Med. 1991; 2: 103-37. https://doi.org/10.1177/10454411910020010201
  11. Rateitschak-Pluss EM, Hefti A, Lortscher R, Thiel G. Initial observation that cyclosporin-A induces gingival enlargement in man. J Clin Periodontol. 1983; 10: 237-46. https://doi.org/10.1111/j.1600-051X.1983.tb01272.x
  12. Wysocki GP, Gretzinger HA, Laupacis A, Ulan RA, Stiller CR. Fibrous hyperplasia of the gingiva: a side effect of cyclosporin A therapy. Oral Surg Oral Med Oral Pathol. 1983; 55: 274-8. https://doi.org/10.1016/0030-4220(83)90327-4
  13. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of druginduced gingival overgrowth. J Clin Periodontol. 1996; 23: 165-75. https://doi.org/10.1111/j.1600-051X.1996.tb02072.x
  14. Niimi A, Tohnai I, Kaneda T, Takeuchi M, Nagura H. Immunohistochemical analysis of effects of cyclosporin A on gingival epithelium. J Oral Pathol Med. 1990; 19: 397-403. https://doi.org/10.1111/j.1600-0714.1990.tb00867.x
  15. Kinane DF, Drummond JR, Chisholm DM. Langerhans cells in human chronic gingivitis and phenytoin-induced gingival hyperplasia. Arch Oral Biol. 1990; 35: 561-4. https://doi.org/10.1016/0003-9969(90)90088-R
  16. Karlinsky JB, Goldstein RH. Regulation of sulfated glycosaminoglycan production by prostaglandin E2 in cultured lung fibroblasts. J Lab Clin Med. 1989; 114: 176-84.
  17. Sugano N, Ito K, Murai S. Cyclosporin A inhibits collagenase gene expression via AP-1 and JNK suppression in human gingival fibroblasts. J Periodontal Res. 1998; 33: 448-52.
  18. Kataoka M, Shimizu Y, Kunikiyo K, Asahara Y, Yamashita K, Ninomiya M, Morisaki I, Ohsaki Y, Kido JI, Nagata T. Cyclosporin A decreases the degradation of type I collagen in rat gingival overgrowth. J Cell Physiol. 2000; 182: 351-8. https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<351::AID-JCP5>3.0.CO;2-U
  19. Yamaguchi M, Naruishi K, Yamada-Naruishi H, Omori K, Nishimura F, Takashiba S. Long-term cyclosporin A exposure suppresses cathepsin-B and -L activity in gingival fibroblasts. J Periodontal Res. 2004; 39: 320- 6. https://doi.org/10.1111/j.1600-0765.2004.00746.x
  20. Barber MT, Savage NW, Seymour GJ. The effect of cyclosporin and lipopolysaccharide on fibroblasts: implications for cyclosporin-induced gingival overgrowth. J Periodontol. 1992; 63: 397-404. https://doi.org/10.1902/jop.1992.63.5.397
  21. Bartold PM. Regulation of human gingival fibroblast growth and synthetic activity by cyclosporine-A in vitro. J Periodontal Res. 1989; 24: 314-21. https://doi.org/10.1111/j.1600-0765.1989.tb00876.x
  22. Thomason JM, Seymour RA, Ellis J. The periodontal problems and management of the renal transplant patient. Ren Fail. 1994; 16: 731-45. https://doi.org/10.3109/08860229409044903
  23. Seymour RA, Heasman PA. Drugs and the periodontium. J Clin Periodontol. 1988; 15: 1-16. https://doi.org/10.1111/j.1600-051X.1988.tb01549.x
  24. Somacarrera ML, Hernandez G, Acero J, Moskow BS. Factors related to the incidence and severity of cyclosporin-induced gingival overgrowth in transplant patients. A longitudinal study. J Periodontol. 1994; 65: 671-5. https://doi.org/10.1902/jop.1994.65.7.671
  25. Hefti AF, Eshenaur AE, Hassell TM, Stone C. Gingival overgrowth in cyclosporine A treated multiple sclerosis patients. J Periodonto l. 1994; 65: 744-9. https://doi.org/10.1902/jop.1994.65.8.744
  26. Sooriyamoorthy M, Gower DB, Eley BM. Androgen metabolism in gingival hyperplasia induced by nifedipine and cyclosporin. J Periodontal Res. 1990; 25: 25-30. https://doi.org/10.1111/j.1600-0765.1990.tb01204.x
  27. Sooriyamoorthy M, Harvey W, Gower DB. The use of human gingival fibroblasts in culture for studying the effects of phenytoin on testosterone metabolism. Arch Oral Biol. 1988; 33: 353-9. https://doi.org/10.1016/0003-9969(88)90069-6
  28. Harel-Raviv M, Eckler M, Lalani K, Raviv E, Gornitsky M. Nifedipineinduced gingival hyperplasia. A comprehensive review and analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995; 79: 715-22. https://doi.org/10.1016/S1079-2104(05)80306-3
  29. Wahlstrom E, Zamora JU, Teichman S. Improvement in cyclosporineassociated gingival hyperplasia with azithromycin therapy. N Engl J Med. 1995; 332: 753-4. https://doi.org/10.1056/NEJM199503163321116
  30. Hernandez G, Arriba L, Lucas M, de Andres A. Reduction of severee gingival overgrowth in a kidney transplant patient by replacing cyclosporin A with tacrolimus. J Periodontol. 2000; 71: 1630-6. https://doi.org/10.1902/jop.2000.71.10.1630
  31. Camargo PM, Melnick PR, Pirih FQ, Lagos R, Takei HH. Treatment of drug-induced gingival enlargement: aesthetic and functional considerations. Periodontol 2000. 2001; 27: 131-8. https://doi.org/10.1034/j.1600-0757.2001.027001131.x
  32. Babcock JR. The successful use of a new therapy for dilantin gingival hyperplasia. Periodontics. 1965; 149: 196-9.
  33. Gomez E, Sanchez-Numez M, Sanchez JE, Corte C, Aguado S, Potal C, Bltar J, Alvarez-Grande J. Treatment of cyclosporin-induced gingival hyperplasia with azithromycin. Nephrol Dial Transplant. 1997; 12: 2694-7. https://doi.org/10.1093/ndt/12.12.2694
  34. Citterio F, Di Pinto A, Borzi MT, ScatàMC, Foco M, Pozzetto U, Castagneto M. Azithromycin treatment of gingival hyperplasia in kidney transplant recipients is effective and safe. Transplant Proc. 2001; 33: 2134-5. https://doi.org/10.1016/S0041-1345(01)01973-X
  35. Tokgiz B, Sari HI, Yildiz O, Aslan S, Sipahioglu M, Okten T, Oymak O, UtasC. Effects of azithromycin on cyclosporine-induced gingival hyperplasia in renal transplant patients. Transplant Proc. 2004; 36: 2699- 702. https://doi.org/10.1016/j.transproceed.2004.09.059
  36. Kim JY, Park SH, Cho KS, Kim HJ, Lee CK, Park KK, Choi SH, Chung WY. Mechanism of azithromycin treatment on gingival overgrowth. J Dent Res. 2008; 87: 1075-9. https://doi.org/10.1177/154405910808701110
  37. Emonard HP, Remacle AG, Noël AC, Grimaud JA, Stetler-Stevenson WG, Foidart JM. Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase. Cancer Res. 1992; 52: 5845-8.
  38. Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res. 1998; 58: 3743-50.
  39. Ellis JS, Seymour RA, Taylor JJ, Thomason JM. Prevalence of gingival overgrowth in transplant patients immunosuppressed with tacrolimus. J Clin Periodontol. 2004; 31: 126-31. https://doi.org/10.1111/j.0303-6979.2004.00459.x
  40. James JA, Boomer S, Maxwell AP, Hull PS, Short CD, Campbell BA, Johnson RW, Irwin CR, Marley JJ, Spratt H, Linden GJ. Reduction in gingival overgrowth associated with conversion from cyclosporin A to tacrolimus. J Clin Periodontol. 2000; 27: 144-8. https://doi.org/10.1034/j.1600-051x.2000.027002144.x
  41. de Oliveira Costa F, Diniz Ferreira S, de Miranda Cota LO, da Costa JE, Aguiar MA. Prevalence, severity, and risk variables associated with gingival overgrowth in renal transplant subjects treated under tacrolimus or cyclosporin regimens. J Periodontol. 2006; 77: 969-75. https://doi.org/10.1902/jop.2006.050327
  42. Paixao CG, Sekiguchi RT, Saraiva L, Pannuti CM, Silva HT, Medina- Pestana JO, Romito GA. Gingival overgrowth among patients medicated with cyclosporin A and tacrolimus undergoing renal transplantation: a prospective study. J Periodontol. 2011; 82: 251-8. https://doi.org/10.1902/jop.2010.100368
  43. Orme ME, Jurewicz WA, Kumar N, McKechnie TL. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes. Pharmacoeconomics. 2003; 21: 1263-76. https://doi.org/10.2165/00019053-200321170-00003